NEWS from SNGX
Corporate Presentation Now Available
look @ our homepage
Forward-Looking Statements
This presentation contains forward-looking statements, which are generally
statements that are not historical facts. Forward-looking statements can be identified
by the words "expects," "anticipates," "believes," "intends," "estimates," "plans," "will,"
"outlook“ and similar expressions. Forward-looking statements are based on
management’s current plans, estimates, assumptions and projections, and speak only
as of the date they are made. We undertake no obligation to update any forwardlooking statement in light of new information or future events, except as otherwise
required by law. Forward-looking statements involve inherent risks and uncertainties,
most of which are difficult to predict and are generally beyond our control. Actual
results or outcomes may differ materially from those implied by the forward-looking
statements as a result of the impact of a number of factors, many of which are
discussed in more detail in our Annual Report on Form 10-K and our other reports
filed with the Securities and Exchange Commission. The forward-looking statements
in this presentation speak only as of the date of the presentation and Soligenix, Inc.
assumes no obligation to update or revise any forward-looking statements as a result
of new information or future events.
2Investment Highlights
3
• Diverse pipeline with eight (8) potential value drivers in development
o Expertise in specialized development areas of GI, cancer supportive care and biodefense
o Innovative products addressing high unmet medical needs
o Potential for multiple co-development and/or out-licensing opportunities
o Experienced management and Board of Directors
• Large underserved target markets
o Multiple programs targeting indications with at least $200M+ markets
o Majority of pipeline programs in orphan (rare) diseases
• Robust news flow potential over next 24 months
o Four programs ready for Phase 2, including SGX203 for pediatric Crohn's disease and
SGX942 for oral mucositis
o Multiple new grant applications filed and in process, including recent BARDA invitation for
potential multi-million dollar contract proposal for GI ARS
o Currently in discussions with DoD for RiVaxTM
pursuant to RFI for a fully developed heat
stable ricin toxin vaccine
• Capital efficient with strong track record of sourcing non-dilutive funding
o Significant NIH/FDA grant support for most programs
o >$25M awarded to date through NIH and FDA grants
News 
Market Data 
Discover 
AI
